Cagrilintide Benefits: What Studies Report

How this page frames "benefits"

Cagrilintide is a long-acting analogue of the pancreatic hormone amylin; the molecule's design, acylation strategy and preclinical characterisation were described in a medicinal-chemistry report on the development of cagrilintide as a long-acting amylin analogue (PMID 34288673). Nothing here is a statement about what the compound will do for any individual. Each section describes what a study design measured, in whom, and the direction of effect that researchers reported. Where the evidence is preclinical, it is labelled preclinical; where an outcome people ask about has not been tested in cagrilintide trials, that gap is stated plainly. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision.

Body weight: cagrilintide alone

The largest dedicated monotherapy dataset came from a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial in people with overweight and obesity, which tested once-weekly cagrilintide at 0.3, 0.6, 1.2, 2.4 and 4.5 mg against placebo and against liraglutide 3.0 mg over 26 weeks (PMID 34798060). In that trial, researchers reported mean body-weight reductions of roughly 6% to 11% across the cagrilintide dose groups compared with about 3% on placebo, with the larger reductions at the higher doses (PMID 34798060). The study was a dose-finding exercise, not an outcomes trial: it was designed to characterise dose–response and tolerability, not to show downstream health events.

A systematic review and meta-analysis of cagrilintide alone and in combination with semaglutide as anti-obesity medications pooled the available randomised data and reported greater weight reduction with cagrilintide-containing regimens than with comparators, alongside a higher frequency of gastrointestinal adverse events (PMID 39676787).

Body weight: cagrilintide co-administered with semaglutide

Phase 1b

The first combination data came from a randomised, controlled phase 1b trial that assessed safety, tolerability, pharmacokinetics and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management (PMID 33894838). Its stated purpose was exposure and tolerability characterisation; body-weight change was measured as a pharmacodynamic endpoint rather than as a definitive efficacy result, and researchers reported that the combination was tolerated at the dose levels examined (PMID 33894838).

Phase 2 in type 2 diabetes

A multicentre, randomised, double-blind, active-controlled phase 2 trial compared once-weekly cagrilintide 2.4 mg co-administered with once-weekly semaglutide 2.4 mg against semaglutide 2.4 mg in adults with type 2 diabetes, and researchers reported greater reductions in HbA1c and in body weight with the co-administered regimen than with semaglutide alone (PMID 37364590).

Phase 3

Two phase 3 randomised trials published in 2025 reported the largest body-weight datasets. In adults with overweight or obesity without diabetes, the trial of coadministered cagrilintide and semaglutide reported a mean body-weight reduction of approximately 20% at week 68 with the combination, compared with approximately 3% with placebo, and with intermediate reductions in the semaglutide-alone and cagrilintide-alone groups (PMID 40544433). In adults with overweight or obesity and type 2 diabetes, the companion trial of cagrilintide–semaglutide reported greater reductions in body weight and in HbA1c than placebo over the same 68-week design (PMID 40544432). Both trials measured weight and glycaemic endpoints; neither was designed as a cardiovascular outcome trial (PMID 40544433).

Glycaemic outcomes

Glycaemic endpoints were measured only in the diabetes populations. The phase 2 trial in type 2 diabetes used HbA1c change as its primary endpoint and researchers reported a greater reduction with cagrilintide 2.4 mg plus semaglutide 2.4 mg than with semaglutide 2.4 mg alone (PMID 37364590), and the phase 3 trial in adults with overweight or obesity and type 2 diabetes reported HbA1c reductions with the combination versus placebo (PMID 40544432). For broader class context, a systematic review and network meta-analysis compared GLP-1 receptor agonists on glycaemic control, body weight and lipid profile in type 2 diabetes and ranked agents on those three domains (PMID 38286487); cagrilintide itself is an amylin analogue rather than a GLP-1 receptor agonist, a distinction described in the development report on the molecule (PMID 34288673).

Reported findings at a glance

Mechanism and preclinical work

Amylin signalling is the proposed mechanism behind the satiety and food-intake effects studied in these programmes, and the development paper describing cagrilintide as a long-acting amylin analogue set out the receptor pharmacology and half-life engineering that made once-weekly administration feasible in preclinical models (PMID 34288673). Separate preclinical-to-clinical work on eloralintide, a different amylin receptor agonist, traced a comparable path from discovery through clinical proof of concept and illustrates that the amylin class is still being characterised rather than settled (PMID 41109426). Findings in cell systems and animals do not transfer directly to human outcomes, a limitation the authors of that discovery-to-proof-of-concept report described explicitly (PMID 41109426).

Outcomes with limited or absent cagrilintide-specific evidence

Several outcomes are commonly attached to amylin analogues in general discussion but were not established endpoints in the cagrilintide trials cited here.

• Cardiovascular events. Neither phase 3 trial was a cardiovascular outcome trial; both measured weight and metabolic endpoints over 68 weeks (PMID 40544433). A review of multisystem effects of obesity medications discussed organ-level outcomes across the drug class as a whole rather than establishing them for cagrilintide specifically (PMID 42208956).
• Liver, kidney, sleep apnoea and osteoarthritis endpoints. These are discussed in the class-level review of benefits of obesity medications beyond weight loss (PMID 42208956), but the cagrilintide randomised trials cited on this page reported weight, glycaemic and safety endpoints rather than dedicated organ-outcome endpoints (PMID 40544432).
• Lean mass or muscle preservation. The dose-finding phase 2 trial reported body-weight change as its efficacy measure and did not establish body-composition claims (PMID 34798060).
• Lipids. Comparative lipid data exist for GLP-1 receptor agonists in the network meta-analysis of glycaemic control, body weight and lipid profile in type 2 diabetes (PMID 38286487), not as a standalone cagrilintide result.
• Long-term durability. The longest randomised follow-up in the cited set was the 68-week phase 3 design (PMID 40544433).

Tolerability and Adverse Events: What Studies Report

Gastrointestinal events dominated the adverse-event profile across the programme. In the phase 2 dose-finding trial, researchers reported that gastrointestinal disorders were the most frequent adverse events with cagrilintide, generally mild to moderate and more common at higher doses (PMID 34798060). The phase 1b trial of multiple cagrilintide doses with semaglutide 2.4 mg was designed around safety and tolerability and reported no unexpected safety signals at the doses studied (PMID 33894838). In the phase 2 trial in type 2 diabetes, researchers reported that adverse events with cagrilintide 2.4 mg plus semaglutide 2.4 mg were predominantly gastrointestinal (PMID 37364590), and the phase 3 trial in adults with overweight or obesity reported gastrointestinal adverse events as the most common category with the combination (PMID 40544433). The pooled systematic review and meta-analysis of cagrilintide alone and as Cagrisema similarly reported a higher rate of gastrointestinal adverse events with active treatment than with comparators (PMID 39676787).

Where cagrilintide sits in current reviews

Narrative reviews place cagrilintide within the wider pipeline rather than among established therapies: a review of novel GLP-1-based medications for type 2 diabetes and obesity described amylin analogues and combination regimens among emerging agents under clinical investigation (PMID 41054801), and a clinical review of weight management treatment in obesity summarised pharmacological options alongside lifestyle and surgical approaches (PMID 40865172). Reviews of this type synthesise trial evidence; they do not generate new outcome data, and the authors of the weight-management review framed drug selection as a clinical decision made with a prescriber (PMID 40865172).

Reading the evidence critically

1. Study type matters. A dose-finding phase 2 trial answers a different question from a 68-week phase 3 trial, as the contrasting designs of the cagrilintide monotherapy trial (PMID 34798060) and the phase 3 combination trial (PMID 40544433) illustrate.
2. Population matters. Results in adults with type 2 diabetes (PMID 40544432) differed in magnitude from results in participants without diabetes (PMID 40544433).
3. Combination versus single agent. Much of the reported weight effect came from regimens that included semaglutide 2.4 mg, as in the phase 2 diabetes trial (PMID 37364590), so combination results should not be read as cagrilintide monotherapy results.
4. Averages are not individuals. The pooled estimates in the meta-analysis describe group means and ranges, not predictions for any one person (PMID 39676787).

Anyone weighing this literature against a personal situation should discuss it with a licensed clinician; this page reports what investigators measured and nothing more.

References

• Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (The New England Journal of Medicine, 2025)
• Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (The New England Journal of Medicine, 2025)
• Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial (Lancet, 2023)
• Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial (Lancet, 2021)
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial (Lancet, 2021)
• Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis (Indian Journal of Endocrinology and Metabolism, 2024)
• Development of Cagrilintide, a Long-Acting Amylin Analogue (Journal of Medicinal Chemistry, 2021)
• Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis (BMJ, 2024)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Weight management treatment in obesity (Medicina Clinica, 2025)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept (Molecular Metabolism, 2025)